BPC-157: The Complete Science Guide to the Body Protection Compound

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from proteins found naturally in human gastric juice. It was first isolated and characterized in the early 1990s by researchers studying the protective properties of gastric secretions. The "body protection" name comes from its observed ability to protect and repair various tissues across multiple organ systems.

Unlike synthetic pharmaceuticals designed to target a single receptor, BPC-157 operates through multiple overlapping biological pathways. Systematic reviews have confirmed its influence on multiple gene expression pathways involved in tissue repair and regeneration, with transcriptomic studies showing altered expression of thousands of genes across various tissue types — making it one of the most pleiotropic peptides known to science.

BPC-157's therapeutic potential stems from its action on several key signaling pathways:

VEGFR2 Pathway — BPC-157 activates vascular endothelial growth factor receptor 2, triggering angiogenesis (the formation of new blood vessels). This is critical for tissue repair, as damaged tissue needs new blood supply to heal. Studies show BPC-157 accelerates the formation of functional blood vessels in injured areas.

FAK-Paxillin Pathway — It activates focal adhesion kinase and paxillin complexes, promoting cell migration and tissue attachment. When tissue is damaged, cells need to migrate to the injury site — BPC-157 facilitates this process.

JAK-2 Signaling — Activation of the Janus kinase 2 pathway supports cell survival, growth, and immune response. This helps explain BPC-157's broad anti-inflammatory effects.

Growth Hormone Receptor Expression — BPC-157 enhances growth hormone receptor expression in tendon fibroblasts, which may explain its particular efficacy in tendon and ligament repair.

Nitric Oxide System — It modulates the NO system, which plays critical roles in vasodilation, neurotransmission, and immune function. This contributes to its observed neuroprotective effects.

A 2025 systematic review in orthopaedic sports medicine literature confirmed preclinical efficacy for fractures, tendon ruptures, ligament tears, and muscle injuries. The evidence spans over 30 years of research across hundreds of studies.

Gastrointestinal applications are particularly well-documented: inflammatory bowel disease, GI ulcer healing, NSAID-induced injury, and fistula repair. The peptide appears to have a natural affinity for gut tissue, which makes sense given its origins in gastric juice.

Neuroprotection is an emerging area: BPC-157 has shown effects on nerve regeneration and repair in preclinical models, with potential implications for conditions involving nerve damage.

A landmark 2025 pilot human study tested intravenous infusion at 10mg and 20mg doses and showed no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers. The half-life is under 30 minutes, with metabolism in the liver and clearance through the kidneys.

Important context: BPC-157 is not FDA-approved for any medical condition. It is banned in professional sports (WADA prohibited list). Most evidence comes from preclinical (animal) studies. The 2025 human pilot focused on safety, not efficacy.

At ExtraLife, BPC-157 is a cornerstone of our Recovery Protocol ($189/month), paired with TB-500 (Thymosin Beta-4) for a 6-week daily subcutaneous protocol. The combination targets tissue repair from two complementary angles: BPC-157 for angiogenesis and cellular signaling, TB-500 for cell migration and inflammation reduction.

All peptides at ExtraLife are physician-prescribed, sourced from US-licensed compounding pharmacies, and third-party purity tested. Protocol monitoring includes CRP and ESR biomarkers to track inflammatory response. This is regenerative medicine done right — physician-guided, evidence-informed, and rigorously monitored.